Novartis investigative site

Overland Park, Kansas 66215

0 studies enrolling now · 23 studies all time

What they study most

Acute Gouty Arthritis, Acute Gouty Arthritis Flares, Asthma, Atherosclerosis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Plaque Type Psoriasis, Chronic Plaque-type Psoriasis, Chronic Spontaneous Urticaria, Healthy Volunteers, Heart Failure and Reduced Ejection Fraction, Major Depressive Disorder, Moderate to Severe Chronic Plaque-Type Psoriasis

Studies at this site

• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma — Completed
• Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab — Stopped early
• A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines — Completed
• A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Safety Study of LLF580 in Obese Volunteers — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis — Completed
• β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) — Completed
• Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. — Completed
• Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder — Completed
• A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD) — Completed
• Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder — Completed
• Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis — Completed
• Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment — Stopped early
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) — Completed
• 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis — Completed
• Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis — Completed
• Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens — Completed
• Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients — Completed
• Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease — Completed